Abstract
Midazolam is a parenteral benzodiazepine with sedative, amnesic, anxiolytic, muscle relaxant and anticonvulsant properties. The drug exerts its clinical effect by binding to a receptor complex which facilitates the action of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Midazolam has a faster onset and shorter duration of action than other benzodiazepines such as diazepam and lorazepam. The most serious adverse events associated with midazolam in children include hypoventilation, decreased oxygen saturation, apnoea and hypotension. It is water soluble in the commercially prepared formulation but becomes lipid soluble at physiological pH and can then cross the blood brain barrier. It is metabolised in the liver by the cytochrome P450 system, and its chief metabolite is 1-hydroxymethyl midazolam. The latter is conjugated to the glucuronide form, and it has only minimal biological activity. Midazolam is excreted primarily by the kidney. Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg. Doses given to children must be calculated on a mg/kg basis. For children 6 months to 5 years of age the initial dose is 0.05 to 0.1 mg/kg. A total dose up to 0.6 mg/kg titrated slowly may be necessary to achieve the desired endpoint. For children 6 to 12 years of age the initial dose is 0.025 to 0.05 mg/kg with a total dose up to 0.4 mg/kg to achieve the desired end-point.
Similar content being viewed by others
References
Reves JG, Glass PS, Lubarsky DA. Nonbarbiturate intravenous anesthetics. In: Miller RD, editor. Anesthesia. 4th ed. New York: Churchill-Livingstone, 1994: 247–89.
Zorumski CF, Isenberg KE. Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry. 1991; 148: 162–73.
Kehlet H. Surgical stress: the role of pain and analgesia. Br J Anaesth. 1989; 63: 189–95.
Kehlet H. The stress response to surgery: release mechanisms and the modifying effect of pain relief. Acta Chir Scand 1989; Suppl. 550: 22–8.
Ryder W, Wright PA. Dental sedation: a review. Br Dent J. 1988; 165: 207–16.
Carrougher JG, Kadakia S, Shaffer RT, et al. Venous complications of midazolam versus diazepam. Gastrointest Endosc. 1993; 39: 396–9.
Ginsberg GG, Lewis JH, Gallagher JE, et al. Diazepam versus midazolam for colonoscopy: a prospective evaluation of predicted versus actual dosing requirements. Gastrointest Endosc. 1992; 38: 651–6.
Bianchi Porro G, Baroni S, Parente F, et al. Midazolam versus diazepam as premedication for upper gastrointestinal endoscopy: a randomized, double-blind, crossover study. Gastrointest Endosc. 1988; 34: 252–4.
Bardhan KD, Morris P, Taylor PC, et al. Intravenous sedation for upper gastrointestinal endoscopy: diazepam versus midazolam. BMJ. 1984; 288: 1046.
Lloyd-Thomas AR, Booker PD. Infusion of midazolam in paediatric patients after cardiac surgery. Br J Anaesth. 1986; 58: 1109–15.
Morselli PL, Principi N, Tognoni G, et al. Diazepam elimination in premature and full term infants, and children. J Perinat Med. 1973; 1: 133–41.
Kanto JH. Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics, and efficacy in insomnia and anesthesia. Pharmacotherapy. 1985; 5: 138–55.
Reves JG, Fragen RL, Vinik R, et al. Midazolam: pharmacology and uses. Anesthesiology. 1985; 62: 310–24.
Booker PD, Beechey A, Lloyd-Thomas AR. Sedation for children requiring artificial ventilation using an infusion of midazolam. Br J Anaesth. 1986; 58: 1104–8.
Tolia V, Brennan S, Aravind MK, et al. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. J Pediatr. 1991; 119: 467–71.
Hartwig S, Roth B, Theisohn M. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the pediatric intensive care unit. Eur J Pediatr. 1991; 150: 784–8.
Versed Product Information. Nutley, New Jersey: Roche Laboratories, 1997.
McNabb AT, Levine M, Glick N, et al. Midazolam following open heart surgery in children: haemodynamic effects of a loading dose. Paediatr Anaesth. 1996; 6: 387–97.
Kumar SP. Adverse drug reactions in the newborn. Ann Clin Lab Sci. 1985; 15: 195–203.
Baziel GM, Gimbriere JS, Booy LH. Benzodiazepine withdrawal reaction in two children following discontinuation of sedation with midazolam. Ann Pharmacother. 1993; 27: 579–81.
Bergman I, Steeves M, Buckart G, et al. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fetanyl administration. J Pediatr. 1991; 119: 644–9.
Hughes J, Gill A, Leach HJ, et al. A prospective study of the adverse effects of midazolam on withdrawal in critically ill children. Acta Paediatr. 1994; 83: 1194–99.
Baziel GM, Gimbrere JS. Benzodiazepine withdrawal syndrome in two children following discontinuation of high dose midazolam [abstract]. Intensive Care Med. 1990; 16: 5119.
Garland DS, Dunne WM, Havens P, et al. Peripheral intravenous catheter complications in critically ill children: a prospective study. Pediatrics. 1992; 89: 1145–50.
Brown WJK, Buist NR, Gipson HT, et al. Fatal benzyl alcohol poisoning in a neonatal intensive care unit [letter]. Lancet. 1982; I: 1250.
Kumar SP. Adverse drug reactions in the newborn. Ann Clin Lab Sci. 1985; 15: 195–203.
Gershank J, Boeder B, Ensley H, et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982; 307: 1384–8.
Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989; 17 Suppl. 1: 29–67.
Burtin P, Jacqz-Aigrain E, Girard P. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther. 1994; 56: 615–25.
Greenblatt DJ, Ehrenberg BL, Scavone JM, et al. Effect of infusion rate on the kinetic-dynamic relationship for intravenous midazolam [abstract]. Clin Pharmacol Ther. 1993; 53: 218.
Klotz U, Reimann IW. Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmacokinet. 1984; 9: 469–74.
Payne K, Matteyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol. 1989; 37: 267–72.
Wandel C, Böcker R Bönrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anesth. 1994; 73: 658–61.
Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995; 29: 619–24.
Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics. 1994; 4: 11–20.
Zeigler WH, Schalch E, Leishman B, et al. Comparison of the effects of intravenously administered miazolam, triazolam, and their hydroxy metabolites. Br J Clin Pharmacol 1983; Suppl. 1: 63S–69S.
Paine MF, Shen DD, Kinze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996: 60(1): 14–24.
Thummel KE, O’shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996; 59(5): 491–502.
Arendt RM, Greenblatt DJ, Liebisch DC, et al. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology. 1987; 93: 72–6.
Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet. 1981; 6: 88–105.
Jones RD, Visram AR, Chan MM, et al. Acomparison of three induction agents in paediatric anaesthesia — cardiovascular effects and recovery. Anaesth Intensive Care. 1994; 22: 545–55.
Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol. 1991; 41(4): 355–7.
Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol. 1990; 39(2): 191–2.
Jacqz-Aigrain E, Daoud P, Burtin P, et al. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur J Clin Pharmacol. 1992; 42(3): 329–32.
Hughes J, Gill AM, Mulhearn H, et al. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother. 1996; 30: 27–30.
Patel IH, Soni PP, Fukuda EK, et al. The pharmacokinetics of midazolam in patients with congestive heart failure. Br J Clin Pharmacol. 1990; 29: 565–9.
Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989; 29: 272–7.
Trouvin JH, Farinotti R, Haberer JP, et al. Pharmacokinetics of midazolam in anaesthetised cirrhotic patients. Br J Anaesth. 1988; 60: 762–7.
Driessen JJ, Vree TB, Guelen PJM. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg. 1991; 42: 149–55.
Jacqz-Aigrain E, Daoud P, Burtin P, et al. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet. 1994; 344: 646–50.
Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981; 30: 653–61.
Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993; 53: 298–305.
Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil tretments. Br J Clin Pharmacol. 1994; 37: 221–5.
Klotz U, Ziegler G, Ludwig L, et al. Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. J Clin Pharmacol. 1985; 25: 400–6.
Shannon M, Albers G, Burkhart K. Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The flumazenil pediatric study group. J Pediatr. 1997; 131: 582–6.
Hickey PR, Wessel DL, Streitz SL, et al. Transcatheter closure of atrial septal defects: hemodynamic complications and anesthetic management. Anesth Analg. 1992; 74: 44–50.
Tolia V, Fleming SL, Kauffman RE. Randomized, double-blind trial of midazolam and diazepam for endoscopic sedation in children. Dev Pharmacol Ther. 1990; 14: 141–7.
Bahal-O’Mara N, Nahata MC, Murray RD, et al. Sedation with meperidine and midazolam in pediatric patients undergoing endoscopy. Eur J Clin Pharmacol. 1994; 47: 319–23.
Sandler ES, Weyman C, Conner K, et al. Midazolam versus fentanyl as premedication for painful procedures in children with cancer. Pediatrics. 1992; 89: 631–4.
Friedman AG, Mulhern RK, Fairclough D, et al. Midazolam premedication for pediatric bone marrow aspiration and lumbar puncture. Med Pediatr Oncol. 1991; 19: 499–504.
Sheridan RL, McEttrick M, Bacha G, et al. Midazolam infusion in pediatric patients with burns who are undergoing mechanical ventilation. J Burn Care Rehabil. 1994; 15: 515–8.
Rosen DA, Rosen KR. Midazolam for sedation in the paediatric intensive care unit. Intensive Care Med. 1991; 17: S15–S19.
Salonen M, Kanto J, Iisalo E, et al. Midazolam as an induction agent in children: a pharmacokinetic and clinical study. Anesth Analg. 1987; 66: 625–8.
Ilkhanipour K, Juels CR, Langdorf MI. Pediatric pain control and conscious sedation: a survey of emergency medicine residencies. Acad Emerg Med. 1994; 1: 368–72.
Shane SA, Fuchs SM, Khine H. Efficacy of rectal midazolam for the sedation of preschool children undergoing laceration repair. Ann Emerg Med 1994 24: 1065–73.
Kuman A, Bleck TR. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med. 1992; 20: 483–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blumer, J.L. Clinical Pharmacology of Midazolam in Infants and Children. Clin Pharmacokinet 35, 37–47 (1998). https://doi.org/10.2165/00003088-199835010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199835010-00003